Settled

Do PCSK9 inhibitors improve all-cause mortality versus placebo?

Mostly studied in coronary & atherosclerotic disease.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

Very likely. So far, repeated by independent trials.

NoUnsureYes
Belief
1.00 (range 0.85–1.00)
Trials for
2
Trials against
0
Inconclusive
1

Already under way

The evidence so far

Registered trials
33
With posted results
3
Published papers
10

Of 14 decided analyses: 9 favor pcsk9 inhibitors, 5 find no difference, 0 favor the comparator.

Papers

Trials

See every trial in the evidence map →